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Abstract
Background: The COVID-19 pandemic has placed an unprecedented strain on health systems, with rapidly
increasing demand for healthcare in hospitals and intensive care units (ICUs) worldwide. As the pandemic escalates,
determining the resulting needs for healthcare resources (beds, staff, equipment) has become a key priority for many
countries. Projecting future demand requires estimates of how long patients with COVID-19 need different levels of
hospital care.
Methods: We performed a systematic review of early evidence on length of stay (LoS) of patients with COVID-19 in
hospital and in ICU. We subsequently developed a method to generate LoS distributions which combines summary
statistics reported in multiple studies, accounting for differences in sample sizes. Applying this approach, we provide
distributions for total hospital and ICU LoS from studies in China and elsewhere, for use by the community.
Results: We identified 52 studies, the majority from China (46/52). Median hospital LoS ranged from 4 to 53 days
within China, and 4 to 21 days outside of China, across 45 studies. ICU LoS was reported by eight studies—four each
within and outside China—with median values ranging from 6 to 12 and 4 to 19 days, respectively. Our summary
distributions have a median hospital LoS of 14 (IQR 10–19) days for China, compared with 5 (IQR 3–9) days outside of
China. For ICU, the summary distributions are more similar (median (IQR) of 8 (5–13) days for China and 7 (4–11) days
outside of China). There was a visible difference by discharge status, with patients who were discharged alive having
longer LoS than those who died during their admission, but no trend associated with study date.
Conclusion: Patients with COVID-19 in China appeared to remain in hospital for longer than elsewhere. This may be
explained by differences in criteria for admission and discharge between countries, and different timing within the
pandemic. In the absence of local data, the combined summary LoS distributions provided here can be used to model
bed demands for contingency planning and then updated, with the novel method presented here, as more studies
with aggregated statistics emerge outside China.
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Background
As of April 28, 2020, there have been over 3 million con-
firmed cases of COVID-19 and more than 200,000 deaths
across 185 countries and territories [1]. Health systems
are challenged by the influx of patients as SARS-CoV-2,
the pathogen causing COVID-19, has spread through-
out the world since its emergence in late December
2019 [2–6]. The risks of healthcare services being over-
whelmedweremost dramatically illustrated in Italy, where
a rapid increase of COVID-19 cases needing hospitali-
sation pushed a well-equipped health system of 3.2 hos-
pital beds per 1000 people to breaking point [7]. This
raises serious concerns over the potential impact on more
resource-constrained health systems in low- and middle-
income countries (LMICs) as epidemics begin to expand
across Africa and South America.
Understanding and predicting hospital bed demand
(as well as associated staff or equipment requirements)
provide crucial evidence for decision-making and con-
tingency planning (7, 8). Predicting demand for hospital
services requires an estimate of the number of patients
requiring hospitalisation and an estimate of how long each
person will require hospital care. It is possible to model
the rate of hospitalisation in many settings based on esti-
mated epidemic curves. However, estimating length of
stay (LoS) in hospitals requires observation of individual
patient pathways.
COVID-19 presents at varying levels of severity. Hos-
pital care can vary from general ward-based care to high
dependency units with oxygen support to intensive care
where patients may be intubated for mechanical ventila-
tion [8–10]. The LoS is likely to depend on the level of care
required, as well as the geographic setting due to varying
COVID-19 care guidelines. For example, some hospitals
in China were initially used as isolation settings [11, 12].
As knowledge of effective treatments changes, the path-
ways, staff, beds, and equipment required are also likely
to affect the duration and level of care needed. Moreover,
patient characteristics—such as age and comorbidities—
impact disease severity [8, 12–14] and are likely to influ-
ence LoS. If differences are significant, then capacity plan-
ning may need to account for these characteristics to pro-
vide accurate predictions of the number of beds required
at each level of care. Modelling studies predicting bed
occupancy published so far have broadly relied on very
few sources of information for LoS estimates, which were
often derived from very different settings [15–22]. Esti-
mates for LoS can be obtained from a variety of studies,
but are often an incidental result rather than a study’s pri-
mary outcome, and typically, only summary statistics are
reported. In general, LoS distributions are right-skewed
due to a minority of patients with long hospital stays and
are often modelled using gamma, log-normal, or Weibull
distributions [23] (although log-normal is less preferred
due to its heavier tails). A particular challenge is how to
synthesise appropriate LoS distributions from a range of
relevant sources in similar settings, capturing the vari-
ation both within and between them. Incorporating the
uncertainty and stochasticity in parameters using a dis-
tribution, rather than fixed point estimates (such as the
mean over all studies), allows for more realistic model
predictions.
We performed a systematic review to identify the cur-
rent evidence on LoS for COVID-19 patients worldwide.
We also present a method for generating LoS summary
distributions by combining information from different
summary statistics (mean and medians) reported in mul-
tiple studies, and accounting for differences in sample
sizes. This aims to include all the variation between stud-
ies, to obtain a distribution that covers all plausible LoSs.
Although similar in the sense of synthesising multiple
sources, this is unlike a classicmeta-analysis which aims to
get a more precise estimate of a quantity assumed as being
a fixed point value. In doing this work, we aim to inform
the efforts of modellers and policy makers to better antic-
ipate healthcare needs during the evolving COVID-19
pandemic.
Methods
Search strategy
This study was conducted following the Preferred Report-
ing Items for Systematic Reviews (PRISMA) guidelines
(9). We searched the bibliographic databases Embase and
Medline, as well as the online pre-print archive medRxiv.
The latter was expected to be an important source due
to the current rapid development of this field; hence,
the fully published literature would capture only a small
proportion of the available information. We included arti-
cles published up to 12 April 2020 that reported a LoS
for COVID-19 patients admitted to hospital. To ensure
all relevant papers were captured, we examined the title,
abstract, and keywords of known studies reporting LoS to
identify relevant search terms. Our search combined the
concepts of COVID-19 (coronavirus, COVID-19, 2019-
nCov, and SARS-CoV-2) with search terms related to
duration of hospital stay (length of stay, admission dura-
tion, admission length, hospital*). The search terms for
hospital stay length were kept broad to capture studies
that report LoS as a secondary outcome. The full search
terms for Embase, Medline, and medRxiv are presented in
the supplementarymaterials. In addition to our systematic
searches, we also checked situation reports from the fol-
lowing organisations to see if they reported LoS estimates:
UK Intensive Care National Audit and Research Centre
(ICNARC), International Severe Acute Respiratory and
Emerging Infection Consortium (ISARIC), World Health
Organization (WHO), the US Centers for Disease Control
and Prevention (CDC), and China CDC and European
CDC (ECDC).
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Inclusion and exclusion criteria
Inclusion criteria are as follows:
1 Studies that reported LoS in hospital for individuals
who were admitted for confirmed COVID-19, or
suspected COVID-19 which was later confirmed
2 Published (either as a pre-print or publication)
between 1 January 2020 and 12 April 2020
Exclusion criteria are as follows:
1 Studies were excluded if LoS was reported for
individuals only admitted to hospital for a reason
other than confirmed or suspected COVID-19
2 Studies where the LoS endpoint was not death or
discharge or continuing stay, for example, transfer to
another hospital
3 Studies which stated that hospitalisation was used as
a form of isolation
4 Studies not published in English
5 Review articles
Screening
The screening process is summarised in Fig. 1. All titles
and abstracts were screened independently by two review-
ers (EMR and SRP). Subsequently, abstracts and full
texts of potentially relevant papers were independently
reviewed by two reviewers (EMR and YJ).
Data extraction and analysis
The data that was extracted from each study is presented
in Supplementary Table A. Data extraction was performed
by EMR, YJ, and ESN and then verified by a second mem-
ber of the study team. Study characteristics (such as study
dates, study population, and study design) were recorded
from each study, including information on the LoS sam-
ple estimate for both total hospital LoS and intensive
care unit (ICU) LoS, as well as sample size, discharge
status, and completeness of follow-up. If multiple LoS esti-
mates were reported for different study populations, these
were all recorded (for example, LoS reported by disease
severity, comorbidities, and treatment groups). One study
specified non-ICU LoS, and this was grouped with total
LoS estimates; ICU LoS was reported separately. Aver-
age patient age and sex distribution (% male) were sum-
marised across all studies by weighted mean and standard
deviation (mean (SD)), according to study sample size.
Where possible, LoS estimates were recorded as median
and interquartile range (IQR). Otherwise, mean and SD,
or in some cases, only a point estimate was provided.
An assessment of bias was considered in these stud-
ies. Reported LoS in the majority of studies was not the
primary outcome; therefore, a formal quality appraisal
was not considered appropriate. Instead, we considered
biases which may directly affect reported LoS. Studies
were assessed as to whether follow-up had been com-
pleted for all included patients, such that an outcome of
discharge or death had been observed for all and none
remained in hospital at the end of the study. If this was
not the case, the final summary of LoS may be biassed by
including only shorter stays which were resolved within
the time frame. As reported above, summaries of patient
characteristics and comorbidities were recorded for each
study where possible; this allowed later comparison of
estimates based on features of the study population and
provided some additional context with which to inter-
pret the LoS estimates. Finally, the risk of bias related
to potentially overlapping populations was also consid-
ered. Studies from the same hospital over the same time
period were identified, and the study with largest sample
size was selected from that group. A list of these stud-
ies is presented in Supplementary table B. LoS was then
summarised including only these selected studies from the
overlapping groups, along with the other non-overlapping
studies. This estimate was then compared to the estimates
based on all studies.
Estimating LoS distributions
Overall summary distributions were created for total hos-
pitalisation LoS and for ICU LoS. Unlike a meta-analysis,
the assumption here was not that each study had esti-
mated an average LoS with some error, but that each
study had captured a portion of the overall LoS distri-
bution across a general population. Each of the studies
provides us with a “sample” which we use to generate
a better idea of the “true” underlying distribution. Our
aim was to therefore incorporate all the variation across
studies in order to obtain a distribution covering all plau-
sible LoS values. We included studies in the estimation
of these summary distributions if they reported both the
sample size along with either the median and IQR or
the mean and standard deviation. If no measure of vari-
ation was provided (either IQR or standard deviation),
the point estimates were included in figures but excluded
from these summary results.
Weibull distributions were fitted to the summary data
from each study, using Nelder-Mead optimisation (imple-
mented in the stats package in R [24]) for those report-
ing medians and IQRs. Specifically, the shape and scale
parameters were varied in order to minimise the squared
distance between the distribution and study quantiles.
Where estimates were presented as a mean, x, and stan-
dard deviation, s, the distribution was fitted by moment-
matching using the mixdist package [25]. The same
approach was also tested using gamma distributions, but
Weibull was marginally preferred with respect to total
squared error in the fitted quantiles. These distributions
were then discretised using the distcrete package in R [26].
A total of 100,000 samples were then drawn from each
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Fig. 1 PRISMA diagram showing the results of the screening process used to identify included studies (n = 52)
of these distributions, with weighting according to their
sample size. Specifically, the study distributions were first
sampled according to a multinomial distribution defined
by the studies’ relative sample sizes, and LoS was then
sampled from each of these sampled distributions. Due
to potential important differences in the characteristics
of each study population, it may not be appropriate to
weight entirely on sample size without considering how
representative the cohort is of the general population.
Therefore, as a sensitivity analysis, we performed the same
analysis without weighting in order to understand how
much this influences the distribution. In some cases, stud-
ies reported LoS according to some stratification and not
over the whole study population. Here, we applied the
samemethod to summarise across the strata and obtain an
estimated median and IQR across the whole population,
validating the approach using examples where the overall
summary statistics were also provided.
All analyses were performed using R version 3.6.3 (29
February 2020).
Results
Study characteristics
The results of our screening process are summarised in
Fig. 1. After removing duplicates, we found a total of 650
potentially eligible studies of which 52 studies met all
the inclusion criteria. These included 32 peer-reviewed
articles from the academic literature, 18 pre-print arti-
cles, and 2 reports from other sources ([27] and [28]).
Several studies reported LoS by specific patient sub-
groups, according to disease severity, comorbidities (kid-
ney injury, liver injury, hypertension, and cardiac injury),
experimental treatments (heparin, lopinavir-ritonavir),
and pregnancy status. A complete description of all
reported LoS estimates is provided in Supplementary
Table B. The key characteristics of the included studies are
summarised in Table 1.
The studies were carried out between 24 December
2019 and 16 April 2020. Although the cut-off was 12 April
2020 for inclusion of published and pre-print studies, the
most recent version of the ICNARC report [28] was used,
which included patients admitted up to 16 April 2020. The
majority of studies were cohort studies (46/52), with four
cross-sectional studies, one case-control, and one ran-
domised control trial (RCT). Two articles were reports
from ongoing data collections (ISARIC [27], 8 April 2020,
and ICNARC [28], 16 April 2020).
Studies were mostly conducted in adults with average
participant age from 19 to 76 years (mean (SD) across
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studies, weighted by sample size, 59 (9.6) years), and over-
all reported only a slightly higher proportion of males
to females (54 (10.9) % male). Three paediatric stud-
ies included patients from newborn to 18 years, with a
weighted mean (SD) of 7 (2.8) years of age [29–31]. For
the majority of studies, LoS was a secondary or inciden-
tal outcome rather than the primary outcome. As a result,
age and sex distributions were not always specific to the
LoS population, and instead reported for the overall study
population. Furthermore, it was not always possible to
accurately interpret the sample size of the population,
nor whether the LoS estimate included still-hospitalised
patients. All LoS data extracted from studies are reported
in Supplementary Table B.
The majority of the included studies (46/52) were based
in China, with a particularly high number reported from
Wuhan (27/46), and many study populations were from
the same outside of China: there was one study from Italy
[32], one for the whole EU region [33], two from the USA
[34, 35], one from the UK [28], and one study that collated
LoS estimates from multiple countries excluding China
(although the majority of the data are from the UK; [27]).
Most studies (43/52) reported LoS for total hospitalisa-
tion only, with four studies reporting LoS for ICU only,
and five studies reporting both. Only 15 studies reported
LoS for study populations with completed follow-up
(patient discharge or death), with 37 reporting estimates
for populations where some patients remained in hospital
or in ICU. The majority of studies only included dis-
charged or dead patients within their LoS estimate, even
if they had incomplete follow-up of the full cohort. How-
ever, for 8 studies, it was unclear whether the reported LoS
included patients who were still hospitalised [33, 34, 36–
41].
Total hospital length of stay
Estimates of the total hospital LoS are summarised in
Fig. 2. Where provided, the overall study estimate of LoS
for each discharge status is presented. For three studies,
LoS was only reported within specific patient subgroups
(relating to cardiac injury [42], COVID-19 recovery trajec-
tory [43], and treatment comparison arms [44]); therefore,
in these cases, we include both estimates. The longest
stays were recorded in a study of five critically ill patients
[45], of whom only three were discharged and all more
than 50 days after admission, which does not appear rep-
resentative of the overall distribution (see Fig. 2, Shen et
al. (2020-01-20)). Excluding this study, the median dura-
tion of hospitalisation ranged from 5 to 29 days. There
was no observed trend with respect to when the study was
conducted (Fig. 2).
Estimates for LoS amongst patients who died in hospital
were generally shorter than those for patients who were
discharged alive, with medians between 4 and 21 days
compared to 4 and 53 days, respectively. This difference is
apparent in Fig. 2, where median LoS was lower for those
discharged alive in 6 out of 8 studies that reported both
outcomes. In studies that reported total hospital LoS by
disease severity (11 studies, Supplementary Fig. A), there
was a trend towards more severe cases having longer LoS.
However, the definition of different levels of severity was
inconsistent between studies so it is not possible to draw
any confident conclusion.
Visual inspection of the study estimates suggested
some evidence of a difference between total hospital LoS
reported within and outside China, but studies outside
China were too few (5/48) for a formal comparison. How-
ever, LoS reported within the ISARIC report [27] in
particular (which includes contributed data from 25 coun-
tries, but with the majority of patients from the UK) gave
a median and IQR (4 days (1–9)) substantially lower than
the weighted mean from the studies from China (15.3
days).
The patient populations observed in these studies cov-
ered a wide range of ages, including three paediatric
studies [29–31]. Amongst patients discharged alive, there
appears to be little difference in average LoS between
studies with the youngest and oldest patients, but the
longest estimates came from studies with average age in
the upper end of the range (Wang et al. [39] and Shi et al.
[44], with average age of 68 and 69, respectively; Supple-
mentary Fig. B). The LoS estimates which included non-
survivors tended to come from studies with older popu-
lations, as is to be expected given the well-documented,
age-dependent fatality rate [46].
ICU length of stay
Median stay in ICU ranged from 5 (IQR 2–9) to 19 (no
IQR reported) days. There appeared to be less of a dif-
ference according to discharge status (alive or dead) than
there was for total LoS (Fig. 3). A total of 8 studies
reported ICU LoS estimates, with the same number of
studies reporting LoS estimates fromChina and outside of
China, and the resulting overall estimates are very similar.
There were too few studies to conduct any comparison by
age or disease severity.
Estimated distributions
Estimated summary hospital LoS distributions for stud-
ies from China and studies outside China are shown in
Fig. 4. The median and IQR for total hospital was esti-
mated to be 14 (10–19) for China and 5 (3–9) excluding
China. This was also repeated for ICU LoS, with a median
and IQR 8 (5–13) for China and 7 (4–11) outside China.
Comparing patient outcomes for total LoS, patients who
died had a shorter LoS distribution (median, 8; IQR, 4–12)
compared with patients who were discharged (median, 14;
IQR, 11–17; Supplementary Fig. C). Studies from China
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Fig. 2 Hospital length of stay, by discharge status. Medians (square) are presented with interquartile range (IQR). Where estimates were reported as
mean and standard deviation, equivalent quantiles have been calculated assuming a Weibull distribution (triangle); if no measure of variation was
reported, only the original mean is presented (circle). The grey dashed lines represent the mean value across all point estimates within that setting,
weighted by sample size. The studies are ordered by the study start date, with most recent at the top. Two studies (Shi et al. (2020-02-02) and Shi et
al. (2020-01-23)) have multiple estimates for the same outcome which represent multiple treatment and comorbidity subgroups, respectively.
Details of these are included in Table 1
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Fig. 3 ICU length of stay, by discharge status. Medians (square) are presented with interquartile range (IQR). Where estimates were reported as
mean and standard deviation, equivalent quantiles have been calculated assuming a Weibull distribution (triangle); if no measure of variation was
reported, only the original mean is presented (circle). The grey dashed lines represent the mean value across all point estimates within that setting,
weighted by sample size. Studies are ordered by the study start date
which had complete follow-up with respect to total hos-
pital LoS were compared with studies with incomplete
follow-up. A slight difference was observed, with shorter
median LoS observed in studies with complete follow-
up (median, 12; IQR, 8–17) compared with incomplete
follow-up (median, 14; IQR, 10–19; Supplementary Fig.
D). This was only performed for total hospital LoS in
China, since no studies from outside China reported com-
pleted LoS for ICU. In addition, LoS estimates of all
studies were compared with estimates where overlapping
patient populations were removed (Supplementary Fig. E).
A list of studies included in this analysis is presented in
Supplementary table B. A small difference was observed,
with longer LoS estimates observed in studies where over-
lapping populations had been removed (n = 17; median,
16; IQR, 11–22) compared with estimates across all stud-
ies (n = 19; median, 14; IQR, 10–19). Again, this sensitiv-
ity analysis was only performed for total hospital LoS in
China, as it was the largest group.
For total hospital LoS in China, five studies were not
included since they only provided point estimates for the
LoS. The point estimates from four of these studies fell
within the IQR of the estimated distribution; however, for
[45], the point estimate was much longer. For total LoS
outside of China, one study reported only a point esti-
mate [33], and this also fell outside of the estimated IQR.
Sensitivity analysis showed that weighting by sample size
had minimal influence on the shape of these distributions
(Supplementary Fig. F).
Discussion
Summary of findings
Understanding how long patients hospitalised with
COVID-19 remain in hospital is critical for planning and
predicting bed occupancy as well as associated staff and
equipment needs. This review found that hospital LoS
observations for COVID-19 patients published in the lit-
erature to date varied from less than a week to nearly
2 months. Stay in intensive care was shorter and less vari-
able, with studies reporting medians of 1 to 3 weeks.
Where LoS was reported according to discharge status,
stay was found to be shorter for those who died than
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Fig. 4 Combined LOS distributions. Samples from the LoS distributions, split by location (China or rest of world) and type (ICU vs total LoS). For each
subset, 100,000 draws were taken. The x-axis was cut at days = 60
for those discharged alive; however, this difference was
only apparent in terms of total stay and not stay in ICU
(no statistical comparison was made). With respect to
practical implications, knowledge of a difference between
survivors and non-survivors is of less use since the out-
come will not be known in advance in order to influence
decision-making. To the authors’ knowledge, this is the
first formal review that has been conducted on hospital
LoS for COVID-19.
The included studies yield some evidence of a difference
between total hospital LoS observed in China and outside
of China, with shorter LoS reported in the latter group (14
days (10–19) vs 5 days (3–9), respectively). However, only
five studies were identified which reported LoS outside of
China; therefore, this comparison is somewhat inconclu-
sive. It may be that LoS is longer in China compared with
other settings due to different criteria for hospital admis-
sion and discharge. A consensus exists across guidelines,
such as ensuring resolution of symptoms and evidence
of two negative PCR samples at least 24 h apart before
discharge [47, 48]; however, differences between settings
may arise as a result of local capacity and strain on the
health system. We attempted to capture this difference
by recording time from onset of symptoms to admission;
however, only one study outside of China reported this
and a comparison was not possible. It is also possible
that, with foresight fromwitnessing the Chinese epidemic,
other countries set less strict criteria for discharge, in
anticipation of stretched capacity. Other countries may
also have used evidence from China to improve treatment
methods and hence shorten LoS. However, this unfortu-
nately appears unlikely as we did not observe a trend when
looking at the reported LoS estimates over time.
In contrast, no difference was observed between set-
tings for ICU LoS, for which there were an equal number
of studies included from within and outside China. It is
important to note that there might be key differences
between ICUs in China compared with other countries,
yet a definition for what constituted an ICU was rarely
reported. Previous studies have found that ICU character-
istics varied widely across geographic regions [49]. Fur-
ther understanding of characteristics of ICUs reporting
LoS for patients with COVID-19 is important in pro-
viding context on the reported estimates and should be
investigated in future studies.
There appeared to be little difference of LoS observed by
age in our results, apart from the fact that studies which
reported deaths tended to have older patient populations.
However, if there is indeed a trend, we were unlikely to
observe strong evidence for it amongst these studies, since
the majority include a similar mix of ages, often tend-
ing towards older cohorts, and the age distribution was
Rees et al. BMCMedicine          (2020) 18:270 Page 17 of 22
not always provided for the specific subgroup who had
LoS recorded. Two studies [27, 38] were included in the
review which reported LoS by age, and they both found
longer LoS associated with older age groups. In addition,
two studies of LoS from the USA which were published
after the search dates also reported a trend for longer
LoS in older age groups [50, 51]. Studies also reported
LoS by disease severity; however, the definitions of disease
severity were not consistent across studies, so we did not
summarise by this.
Limitations and biases
Having been the first country to observe this novel coro-
navirus, published data on COVID-19 patient outcomes
in China is more widely available than from countries
to which the epidemic spread later on. The set of stud-
ies found in this review reflects this bias towards evi-
dence obtained from China, particularly Wuhan. The
small number of studies identified from outside of China
means it is difficult to interpret comparisons across set-
tings. Several studies have been published after our search
dates which provide additional LoS estimates from out-
side of China. A study of 5700 patients from hospitals
in the New York area reported comparable estimates for
total LoS (median 4.5; IQR 2.4–8.1) [51]; however, studies
from Northern Italy [52], Japan [53], and California and
Washington [50] reported longer estimates of LoS. There-
fore, the total LoS outside of China may in fact be longer
than what we concluded. Our code is freely available on
github, and additional studies may easily be added. As
more studies emerge from a broader range of settings, it
would be important to re-evaluate LoS estimates, as there
are likely to be between-country differences that we have
not captured here.
Furthermore, a number of studies include patients from
the same hospital over the same period, for example, Yang
et al. [54] and Wu et al. [55] who both reported patients
from Jin Yin-Tan hospital in Wuhan, and it is possible that
these studies had overlapping study populations. Further-
more, Guan et al. [36] was a national study conducted in
China and ISARIC [27] included 25 countries worldwide;
therefore, these studies may also include patients previ-
ously described. The effect of this double-counting would
be to bias the overall summary statistics towards the LoS
from these settings, and potentially reduce the total vari-
ation. Although this is acknowledged as an issue, it was
not considered as a basis for exclusion since any crite-
ria for selecting one study from the overlapping group
would have been arbitrary and potentially induce another
source of bias in itself. Therefore, we instead chose to
conduct a sensitivity analysis based on a straightforward
selection criteria of largest sample size from those studies
with any potential for overlap, and found little difference
between the estimates of LoS whether overlapping studies
were included or excluded. The overall benefit of inclu-
sion, particularly asmany of these studies reported LoS for
different subgroups, was deemed to outweigh the poten-
tial bias which may arise as a result of overlapping patient
populations.
In this review, we were only able to distinguish between
“total hospital LoS” and “ICU LoS”, with many studies
only reporting a total LoS. This total LoS will include
both general hospital and ICU admissions within it. There
is a need for more granularity with respect to patient
pathways, distinguishing between admissions to different
levels of care within one hospital episode in order to better
inform healthcare contingencies. Patients may, for exam-
ple, be transferred to ICU on more than one occasion
during their stay, which is important to factor in when
ICU capacity is particularly limited.
Changes in hospital demand may have also affected our
estimates. At the beginning of the outbreak and in certain
settings, hospitals were being used to isolate patients who
were unable to isolate effectively at home [11, 12]. This
means that LoS for patients in some of the earlier stud-
ies within this dataset could have been longer due to this
logistical reason, rather than clinical need. Studies which
mentioned this explicitly were excluded, yet theremay still
be others which were not so transparent. In addition, it is
possible that, as hospitals reach the limits of their capacity,
a more stringent triage policy may be implemented and
the most critical patients may not be transferred to ICU.
Despite this, we did not observe a trend when looking at
the reported LoS estimates over time, suggesting that this
is not in fact an important issue in our data.
Finally, many studies had incomplete follow-up with
respect to LoS, and as a result, patients still hospitalised
at the end of the study were not included in the sum-
mary statistics (right-truncation). This will bias estimates
towards shorter LoS, as patients with longer LoS will not
be included. A study by Lapidus et al. [56] investigated
the bias associated with estimating average ICU LoS for
COVID-19 patients based on observed LoS of discharged
patients before follow-up of the entire patient cohort was
completed. As expected, the authors found that the aver-
age LoS estimated at 3 months of follow-up was much
longer than that estimated at 1 month. This potentially
affects our estimates, given that 37 (out of 52) studies
had incomplete follow-up with regard to LoS, although on
comparison the difference between the groups was slight,
and estimates where follow-up was complete were overall
shorter. Several studies included still-hospitalised patients
in their LoS summary without accounting for censoring
[33, 34, 36–41], which potentially alters interpretation of
the values.
Summarising length of stay
We found that LoS is often not the primary measure
of interest in studies which report it; however, it is an
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important parameter when it comes to forecasting bed
occupancy during an outbreak. By conducting this review,
we have systematically gathered a range of published esti-
mates, providing a source from which researchers and
decision-makers can obtain estimates specific to their
population of interest (e.g. with respect to comorbidities)
and allowing comparison of LoS between several different
populations and settings.
There have been numerous previous studies which have
aimed to forecast the number of hospital beds required
for COVID-19 patients [16–22, 57]. Many of these studies
published so far have used point estimates, only originat-
ing from one study which often does not reflect the con-
text of interest. In particular, many used estimates from
Zhou et al. [58] which reported a shorter total hospital
LoS (median 11·0, IQR 7·0–14·0; Fig. 2), and a compara-
ble ICU LoS (median 8·0, IQR 4·0–12·0; Fig. 3), compared
with other studies from China. However, both of these
were still longer than LoS estimates reported by stud-
ies outside of China. This means that the bed-forecasting
studies relying on LoS estimates from Zhou et al. may be
underestimating the number of beds required. This review
has highlighted several potential sources of variation in
LoS and identified common issues and biases which influ-
ence each individual estimate. This gives a motivation for
considering a wider range of values than can be obtained
in a single study, aiming instead to capture the overall
distribution of LoS across a variety of possible patient
trajectories.
Our findings provide both better estimates of the LoS
distribution for patients hospitalised with COVID-19 and
a method for generating these important distributions
going forward. Combined with predictions of disease inci-
dence, models forecasting bed occupancy are used to plan
required hospital capacity and hence are critical for out-
break preparations. The LoS estimate is a critical parame-
ter within such a model, and as such, any predictions are
sensitive to the value or distribution being assumed, with
strong implications for policy and planning. In particu-
lar, the tail of the LoS distribution must not be ignored
since these few patients can block beds for a long time
and form a heavy burden on capacity. Our estimates,
and the proposed method for distribution collation, allow
for improved predictions of this aspect of burden pre-
diction and hence could reduce uncertainty in capacity
preparedness in healthcare settings going forward. This is
of value to countries still experiencing growing epidemics
and those turning attention to the planning for the pos-
sibility of a second wave whilst restarting non-COVID
care.
It is preferable to use data from the setting for which
you are trying to forecast bed occupancy (as was done by
the IHME COVID-19 health service utilisation forecast-
ing team [15]); however, data on completed patient stays
will often not be available until well after the onset of the
epidemic. Furthermore, LMICs may have reduced capac-
ity for surveillance andmonitoring in order to obtain these
data. In such cases, where countries are in the early stages
of an outbreak, it would be better to use a conservative (i.e.
broad) distribution of LoS from another setting. As the
pandemic progresses and more countries observe patients
completing their hospital episodes, it will be possible to
add further setting-specific summaries and improve this
distribution.
As far as the authors are aware, the approach demon-
strated here to summarise median and IQRs across multi-
ple studies has not been proposed before, although there
are similarities with the approach taken by others in the
CMMID Working Group to pool R0 estimates [59]. We
present an intuitive method which exploits two optimi-
sation methods to fit parametric distributions based on
reported summary statistics rather than individual data,
then samples across them. In this way, we capture the
central tendency and overall variation between a set of
quantiles from different study populations. This allows
multiple sources of evidence to be consolidated into a
single distribution which can be used in bed forecasting
going forward. By providing both the code for this analy-
sis and our summary distributions, better bed occupancy
predictions can be made in the future.
Conclusion
This review summarised the available literature to pro-
vide estimates of LoS for total hospital admission and
ICU which can be applied for planning and prepared-
ness for SARS-CoV-2. We found substantial differences
between China and other settings in terms of total hos-
pital stay, but little evidence for an impact on LoS of
time of study, age, or disease severity. We present sum-
mary distributions which can be used within models
making predictions about bed requirements, and sug-
gest that this may be a more robust and realistic way
to characterise LoS than relying on summary data from
just one setting or hospital. The majority of the data pre-
sented in this review comes from China, and as more
data become available, it will be important to update this
with setting-specific LoS estimates. Understanding the
duration of hospitalisation of COVID-19 patients is criti-
cal for providing insights as to when hospitals will reach
capacity, as well predicting associated staff or equipment
requirements.
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